Related references
Note: Only part of the references are listed.Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy
Sudipto Das et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Katerina Chatzidionysiou et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
Axel Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study
Vibeke Strand et al.
JOURNAL OF RHEUMATOLOGY (2012)
Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion
Ulrich A. Walker et al.
RHEUMATOLOGY (2011)
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Richa Mishra et al.
RHEUMATOLOGY INTERNATIONAL (2011)
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
M. C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The Disease Activity Score and the EULAR Response Criteria
Jaap Fransen et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2009)
The Simplified Disease Activity Index and Clinical Disease Activity Index to Monitor Patients in Standard Clinical Care
Daniel Aletaha et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
Axel Finckh et al.
ARTHRITIS AND RHEUMATISM (2007)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
